Posted by Michael Wonder on 17 Apr 2020
FDA accepts for priority review biologics license application for REGN-EB3 to treat Ebola
16 April 2020 - REGN-EB3 developed via same rapid response platform currently being leveraged to develop novel COVID-19 antibody therapy.
Regeneron Pharmaceuticals today announced that the U.S. FDA has accepted for priority review a new biologics license application for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection.
The target action date for the FDA decision is 25 October 2020.
